Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlycoMimetics (GLYC)
NASDAQ:GLYC
Holding GLYC?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -38.03%
|Next Earnings Date:Feb 27, 2025
Earnings Call Sentiment|Neutral
The earnings call revealed challenges with the Phase III trial not meeting its primary endpoint, leading to financial and strategic reassessments. However, there is a commitment to further analyze the rich data collected and ongoing trials continue to explore the potential of uproleselan in AML treatment.Company Guidance
During the Q1 2024 earnings call for GlycoMimetics, the management provided updates on the Phase III study of their lead drug candidate, uproleselan, which unfortunately did not achieve a statistically significant improvement in overall survival for patients with relapsed/refractory acute myeloid leukemia (AML). The trial involved 388 patients across 70 sites in 9 countries, with a median overall survival of 13 months for the uproleselan arm and 12.3 months for the placebo arm. Despite not meeting its primary endpoint, the study's unexpected control group survival rate of over one year is considered unprecedented in this setting. The company plans to conduct a comprehensive analysis of the data in collaboration with medical, statistical, and regulatory experts and intends to present findings at a future medical meeting. Additionally, GlycoMimetics highlighted ongoing studies, including a National Cancer Institute-sponsored Phase II/III trial, and mentioned efforts to manage cash burn and revise budget plans as they proceed with further analyses and discussions with the FDA.Low Discontinuation Rate
The study had a low discontinuation rate of 3%, indicating good patient retention and adherence to the trial protocol.
Rich Data Set for Future Analysis
The study involved 388 patients with an unprecedented follow-up of over 3 years, providing a rich data set for further analysis and potential insights into AML treatment.
Commitment to Further Research
Despite the trial's primary endpoint not being met, GlycoMimetics remains committed to exploring uproleselan's potential in AML and plans to conduct a rigorous analysis of the data.
Ongoing Trials and Future Plans
The National Cancer Institute is sponsoring an ongoing Phase II/III trial evaluating uproleselan in newly diagnosed older patients with AML, and results will be shared when available.
---
GLYC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GLYC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $0.38 | $0.42 | +10.53% |
| Aug 01, 2024 | $0.22 | $0.22 | 0.00% |
| May 06, 2024 | $1.83 | $0.32 | -82.51% |
| Mar 27, 2024 | $2.85 | $3.18 | +11.58% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does GlycoMimetics (GLYC) report earnings?
GlycoMimetics (GLYC) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is GlycoMimetics (GLYC) earnings time?
GlycoMimetics (GLYC) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GLYC EPS forecast?
Currently, no data Available
---